The drug is synthesized with dihydropyridine endings and blocks slow Ca channels. In addition, it inhibits the transmembrane movement of calcium into the region of the cells of the smooth cardiac muscle, as well as the vessels (mainly moves inside the cells of the vascular smooth muscle, and not inside the cardiomyocytes).
Has antianginal, and in addition to hypotensive properties.
The hypotensive effect of amlodipine is provided by its direct relaxing effect on the relatively smooth vascular musculature.
Antianginal effects are due to vasodilatation of arterioles having a peripheral type, as a result of which the OPSS decreases. It should be noted that the rate of heart rate remains almost unchanged, which makes it possible to reduce the consumption of energy expended, as well as the oxygen demand of the myocardium. In addition, the expansion of arteries that have a peripheral or coronary type, and with it arterioles (inside normal and also ischemic areas of the myocardium), as a result of which the amount of oxygen entering the myocardium increases in people with angina of a variant type. The drug prevents the emergence of coronarospasm, provoked by smoking.
People with high blood pressure receiving a single daily dose of drugs provides a reduction in pressure in the period of 24 hours in the positions lying and standing. Slow and gradual onset of the Vasconia's effect allows avoiding a sharp drop in blood pressure.
For people with angina, the use of a single daily dosage of amlodipine increases the duration of exercise, and also delays the occurrence of a new attack of angina with depression of the ST-type segment during exercise. Also, the medicine reduces the incidence of angina attacks and the intake of nitroglycerin.
Individuals with SSS pathologies (including coronary atherosclerosis, in which one vessel is affected, as well as stenosis of the 3+ arteries and narrowing of the carotid arteries) who have suffered myocardial infarction or PTCA in the coronary artery, and in addition to having stenocardia, thickening in the carotid CMY.
In addition, it significantly reduces the rate of death due to cardiovascular disease, stroke with myocardial infarction, as well as coronary artery thrombosis with coronary artery bypass graft. Together with this, it helps to reduce the number of hospitalizations due to unstable angina and progression of CHF, and also reduces the number of procedures for restoring coronary circulation.
The drug does not increase the risk of death or the occurrence of complications that cause death in people with CHF (3-4 functional stage of NYHA) in treatment with diuretics, digoxin, and ACE inhibitors.
In individuals with CHF (grade 3-4 functional grade according to NYHA), which is of non-ischemic origin, the use of Vasconia can cause pulmonary edema.
The drug does not have a negative effect on metabolism, as well as the level of plasma lipids.